Furthermore, the PPN-delivered miR-503 inhibitor effectively modulates endothelial cell expression of miR-503 and its downstream targets, CCNE1 and CDC25a, thereby enhancing endothelial angiogenesis in diabetes-like conditions as demonstrated by tubulogenesis and migration in vitro. Here, CDC25A is linked to diabetes mellitus.